INTRODUCTION

In patients with type 1 diabetes, the glucagon response to hypoglycemia is often sub-normal or absent (1) after a few years duration of the disease. This may be due to impairments in the autonomic stimulation of the alpha-cells, although a contribution of an impaired response to the lowering of blood glucose per se cannot be excluded (2). Furthermore, paracrine mechanisms due to the absent beta-cell function may also be of importance. In contrast, glucagon secretion induced by exercise (3) or an intravenous bolus of arginine seems to be unaltered in type 1 diabetes (4, 5).

Several factors are known to interfere in the secretory response of the alpha-cell, such as catecholamines (6, 7), the local glucose concentration (8–10), the islet nerves (11) and the intra-islet insulin level (12).

Earlier experimental studies have shown that exogenous insulin inhibits basal glucagon secretion (13) and have also demonstrated that a high concentration of insulin may suppress the glucagon response to insulin-induced hypoglycemia in healthy subjects as well as in patients with type 1 diabetes (14–16).

This would suggest that the ambient circulatory level of insulin is of importance for glucagon secretion, which would be of clinical relevance in type 1 diabetes. However, the results showing that insulin inhibits hypoglycemia-induced glucagon secretion in type 1 diabetes do not prove that the direct secretion from the alpha-cells is sensitive to circulating insulin. The glucagon secretion induced by hypoglycemia in these patients is largely indirectly mediated by the autonomic nerves and catecholamines (2). For such a demonstration, it is necessary to examine the influence of insulin on glucagon secretion stimulated by an agent acting directly on the alpha-cells. Since this has never been demonstrated, we have, in the present study, investigated the possible suppressive effect of exogenously administered insulin on glucagon secretion after direct stimulation by arginine in type 1 diabetes. Arginine was used since it is a powerful stimulus in the activation of glucagon secretion and it exerts this effect by a direct
effect on the glucagon producing alpha-cell. In order to achieve an inhibition of the potent stimuli of the alpha-cell by insulin probably through paracrine mechanisms, it was calculated that a high dose of insulin infusion would be needed. This study will provide data on the regulation by insulin of directly stimulated glucagon secretion in type 1 diabetes and will emphasize further the importance of keeping the insulin substitution levels as low as possible.

Subjects and methods

Ten patients with type 1 diabetes (two females), average age 37 (20–58) years, body mass index (BMI) 22.9 ± 2.5 kg m⁻², duration of disease 15 (4–32) years, participated in the study. No patient had significant endogenous production of insulin as revealed from a negative C-peptide test. One patient had pre-proliferative and four had non-proliferative retinopathy; otherwise none had any signs of late diabetic complications. All patients were treated with four daily injections of insulin: short-acting insulin was given before breakfast, lunch and dinner, and intermediate-acting insulin was given at bedtime. No patient had a history of hypoglycemia unawareness. No episode of severe hypoglycemia was reported in the week preceding each experiment. Their glycated hemoglobin (HbA1c) was 6.9 ± 0.5% (normal non-diabetic range < 5.2%) in the low-dose experiment vs 7.0 ± 0.5% in the high-dose experiment. The study protocol was approved by the local ethical committee and all patients gave their informed consent to participate in the study.

Study protocol

All patients’ intermediate-acting insulin was withdrawn 36 h prior to the test. They were admitted to a metabolic ward the day before the test and were given short-acting insulin i.v. The rate of insulin infusion was adjusted on the basis of frequent blood glucose monitoring and was aimed at between 6 and 10 mmol l⁻¹. In the morning after an overnight fast, the patient came to the laboratory at 0730 h and was placed in a comfortable, semi-recumbent position for 30 min before the experiment. A short Tellon catheter was inserted into an antecubital vein on each side, one being used for infusions and the other for blood sampling for insulin, glucagon, growth hormone and C-peptide. A short tellon cannula was placed in a dorsal vein on the right hand which was placed in a warm-air box (Department of Medical Physics, Queens Medical Centre, Nottingham, Notts, UK), heated to 55–60°C to arterialize the venous blood samples for analyses of blood glucose.

Each patient was studied on two occasions separated by at least two weeks. In random order, the patients were given insulin (Actrapid Human, Novo A/S, Copenhagen, Denmark) either as a low-dose infusion (LDT) (244 pmol kg⁻¹ h⁻¹) or as a high-dose infusion (HDT) (1034 pmol kg⁻¹ h⁻¹). The blood glucose was clamped 30 min prior to the experiments and remained clamped during both experiments at a level of 5 mmol l⁻¹ by a variable intravenous infusion of glucose (20%) adjusted at three-minute intervals. Ten milliliters human albumin solution (20 mg ml⁻¹, Albumin, KabiVitrum, Stockholm, Sweden) were added to 490 ml insulin-infusion solution in all experiments.

Following a steady state of blood glucose at a level of 5 mmol l⁻¹ for 30 min, an i.v. bolus of arginine hydrochloride (150 mg kg⁻¹) was given, followed by an infusion of arginine hydrochloride (10 mg kg⁻¹ min⁻¹) for 30 min. Arterialized blood samples for the analysis of blood glucose were obtained every third minute and venous blood samples for the analysis of plasma (p)-C-peptide, p-glucagon, p-growth hormone and p-free insulin were obtained at −5, 0, 5, 10, 20 and 30 min. Blood pressure and pulse rate were recorded at the same intervals.

Analyses

Blood glucose was determined by a glucose analyzer (Yellow Springs Instruments, Yellow Springs, OH, USA). Plasma free insulin was determined according to Nakagawa et al. (17), using commercial radioimmunoassay kits (Pharmacia Diagnostics AB, Uppsala, Sweden) after precipitation of the antibody-bound insulin with 25% polyethylene glycol immediately following the blood collection. Plasma growth hormone was analyzed by radioimmunoassay (18). Plasma C-peptide and p-glucagon samples were obtained in prechilled test tubes containing aprotinin (250 kallikrein-inhibiting U ml⁻¹ blood; Bayer, Leverkusen, Germany). The tubes for p-glucagon also contained 0.084 ml EDTA (0.34 mol l⁻¹). C-peptide levels were measured with a radioimmunoassay technique using rabbit antiserum to synthetic human C-peptide (31 amino-acids). The immunogen was C-peptide N-terminally conjugated to bovine albumin (Euro-Diagnostica, Malmö, Sweden) (19). Glucagon levels were measured with a double-antibody radioimmunoassay in duplicate using guinea pig anti-human glucagon antibodies specific for pancreatic glucagon,¹²⁵I-glucagon as a tracer, and glucagon standard (Linco, St Charles, MO, USA) (20). The intra- and interassay coefficients of variation of determination were 3 and 7% respectively for glucagon.

Statistical analyses

Statistical significance was evaluated by means of a Student’s two-tailed t-test for paired observations, a Wilcoxon signed rank test and analysis of variance (ANOVA) when applicable. P values less than 0.05 were
considered significant. Unless otherwise stated, the data are given as means ± S.E.M.

Results

The mean plasma free concentration of insulin during the LDT was 88 ± 3 pmol l⁻¹ compared with a four times higher concentration of 332 ± 12 pmol l⁻¹ (P < 0.0001) during the HDT. The endogenous insulin secretion, as reflected by the C-peptide level, was close to the detection limit in eight of the patients. There was no difference between LDT and HDT in C-peptide levels before (0.16 ± 0.03 vs 0.16 ± 0.03 nmol l⁻¹) or after (0.20 ± 0.06 to 0.19 ± 0.04 nmol l⁻¹) the arginine administration. Two patients had measurable concentrations and in these two the arginine challenge resulted in a slight increment of the C-peptide level (0.21 and 0.27 nmol l⁻¹), but without any difference between the LDT and HDT.

The mean baseline concentrations of blood glucose were similar in the two tests. In the HDT, the glucose level remained close to the goal, i.e. 5 mmol l⁻¹, throughout the experiment. The same was true for the LDT for the period -30 to 0 min. Thereafter, in the LDT the blood glucose rose to about 5.5 to 6 mmol l⁻¹ (Fig. 1) in spite of the fact that the glucose infusion was markedly reduced and was even stopped in seven of the patients.

During the first 30 min of the clamp (i.e. -30 to 0 min), there was a gradual and pronounced increase in the amount of the i.v. glucose infusion required to maintain euglycemia in both experiments, the difference being that during the HDT the amount infused was about two times higher. The i.v. arginine bolus and infusion had effects on exogenous glucose requirements in both the LDT and HDT as the expected continuous rise in glucose requirements was not seen after time 0. However, the important difference between the tests was that this ‘requirement’ remained at a similar level in the HDT (120 ml/h) while a pronounced reduction was observed in the LDT (from 70 to 5 ml/h, P < 0.009).

The total amount of glucose infused in the period 0 to 30 min was markedly lower in the LDT than in the HDT (7.5 ± 2.5 vs 61.8 ± 5.4 ml, P < 0.0001).

In response to arginine, the p-glucagon and p-growth hormone levels increased significantly in both experiments. The glucagon level had a similar initial prompt increase in both tests. However, after the initial peak, the glucagon level was lower in the HDT than in the LDT (Fig. 1). Also the mean area under the curves of p-glucagon (0–30 min) was significantly smaller in the HDT experiment compared with the LDT experiment (413 ± 45 vs 466 ± 44 pg ml⁻¹ h⁻¹, P = 0.03; Fig. 2). In contrast, no significant difference in either the basal growth hormone level (2.5 ± 1.3 vs 2.2 ± 1.2) or the peak growth hormone level (7.8 ± 2.5 vs 9.0 ± 2.9 µg l⁻¹) was seen between the tests (Fig. 2).

There were no changes in the pulse rate or in blood pressure during either test (data not shown).
Discussion

This study shows that the glucagon response to i.v. arginine is reduced by a high level of circulating insulin in type 1 diabetes. Since arginine exerts its powerful glucagonotropic action through a direct effect on the glucagon-producing alpha-cells, the study provides evidence that insulin participates in the regulation of glucagon secretion in type 1 diabetes through a direct action on the alpha-cells. Previous studies on the effects of insulin on glucagon secretion in type 1 diabetes or in healthy subjects have only indirectly stimulated glucagon secretion, mainly through hypoglycemia (14–16) and our present study thus provides the first evidence that insulin exerts its glucagonostatic action in humans at the level of the alpha-cell in type 1 diabetes.

A difference in the glucose levels following the administration of the bolus of arginine was seen between the LDT and HDT experiments. Hyperglycemia has been shown to suppress glucagon levels and the glucagon response to arginine in normal man and in patients with type 2 diabetes (21–23). In contrast, an exaggerated response to arginine has been observed in patients with type 1 diabetes (24). However, this apparently paradoxical reaction is not attributed to hyperglycemia but to insulin deficiency (24, 25). Therefore, the modest difference in blood glucose (5.8 vs 5.0 mmol/l) between the LDT and HDT cannot explain the difference in glucagon response.

Pharmacological stimulation of glucagon secretion by arginine is mediated through a direct action on the alpha-cells rather than indirectly through other hormones or the autonomic nervous system (26). Therefore, the most likely explanation for the inhibitory action of insulin on arginine-stimulated glucagon secretion in our study is a direct action of insulin on the alpha-cells. Such an action was previously demonstrated in experimental animals (27, 28) and our present study shows that this is also the case in type 1 diabetes patients.

It has previously been shown that even a minimal change in the glucagon levels could result in sustained hyperglycemia in a human deprived of insulin (29, 30). The changes in the glucagon levels seen in the LDT may seem small, but may be of functional importance since they resulted in a marked decrease in the need for supplementary i.v. glucose to maintain euglycemia. However, these experiments were relatively short and this must be kept in mind when interpreting the changes due to the glucose infusion rates.

This implies a need for an insulin substitution in type 1 diabetes in which the basal insulin levels are kept as low as possible.

In conclusion, this study demonstrates that a high level of circulating insulin exerts an inhibitory effect on the glucagon response to arginine in type 1 diabetes. Thus, the suppressive effect of insulin on the glucagon release from the alpha-cell seems to be general and not
dependent on the stimuli. Furthermore, a marginal increase in the glucagon levels appears to exert significant effects on the glucose homeostasis in type 1 diabetes patients.

Acknowledgements
This work was supported by grants from the Bert von Kantzow Foundation, the Karolinska Institute and the Swedish Medical Research Council (grant nos 19x-6589 and 14x-6834).

References